WO2011147981A2 - Neuregulin isoforms, neuregulin polypeptides and uses thereof - Google Patents
Neuregulin isoforms, neuregulin polypeptides and uses thereof Download PDFInfo
- Publication number
- WO2011147981A2 WO2011147981A2 PCT/EP2011/058769 EP2011058769W WO2011147981A2 WO 2011147981 A2 WO2011147981 A2 WO 2011147981A2 EP 2011058769 W EP2011058769 W EP 2011058769W WO 2011147981 A2 WO2011147981 A2 WO 2011147981A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nos
- protein
- polypeptide
- domain
- Prior art date
Links
- 108010029485 Protein Isoforms Proteins 0.000 title claims abstract description 191
- 102000001708 Protein Isoforms Human genes 0.000 title claims abstract description 191
- 102000014413 Neuregulin Human genes 0.000 title description 38
- 108050003475 Neuregulin Proteins 0.000 title description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 164
- 229920001184 polypeptide Polymers 0.000 claims abstract description 160
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 160
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 33
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 155
- 102000004169 proteins and genes Human genes 0.000 claims description 153
- 150000001413 amino acids Chemical class 0.000 claims description 111
- 102000012545 EGF-like domains Human genes 0.000 claims description 87
- 108050002150 EGF-like domains Proteins 0.000 claims description 87
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 80
- 210000004027 cell Anatomy 0.000 claims description 78
- 210000002569 neuron Anatomy 0.000 claims description 71
- 230000014509 gene expression Effects 0.000 claims description 63
- 208000018737 Parkinson disease Diseases 0.000 claims description 62
- 238000011282 treatment Methods 0.000 claims description 50
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 46
- 229920000669 heparin Polymers 0.000 claims description 46
- 229960002897 heparin Drugs 0.000 claims description 46
- 229960003638 dopamine Drugs 0.000 claims description 40
- 208000020925 Bipolar disease Diseases 0.000 claims description 36
- 102000008013 Electron Transport Complex I Human genes 0.000 claims description 36
- 108010089760 Electron Transport Complex I Proteins 0.000 claims description 36
- 102000004899 14-3-3 Proteins Human genes 0.000 claims description 31
- 230000037430 deletion Effects 0.000 claims description 30
- 238000012217 deletion Methods 0.000 claims description 30
- 230000037431 insertion Effects 0.000 claims description 30
- 238000003780 insertion Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 230000035772 mutation Effects 0.000 claims description 27
- 230000002438 mitochondrial effect Effects 0.000 claims description 26
- 102000007469 Actins Human genes 0.000 claims description 25
- 108010085238 Actins Proteins 0.000 claims description 25
- 101710204191 Phosphatidylethanolamine-binding protein 1 Proteins 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 102000005396 glutamine synthetase Human genes 0.000 claims description 24
- 108020002326 glutamine synthetase Proteins 0.000 claims description 24
- 208000024827 Alzheimer disease Diseases 0.000 claims description 23
- 201000006417 multiple sclerosis Diseases 0.000 claims description 23
- 201000000980 schizophrenia Diseases 0.000 claims description 22
- 230000001537 neural effect Effects 0.000 claims description 21
- 101001053503 Homo sapiens Dihydropyrimidinase-related protein 2 Proteins 0.000 claims description 17
- 101000685001 Homo sapiens Stromal cell-derived factor 2-like protein 1 Proteins 0.000 claims description 17
- 102100023183 Stromal cell-derived factor 2-like protein 1 Human genes 0.000 claims description 17
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 claims description 17
- 108010027273 Valosin Containing Protein Proteins 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 102000044591 ErbB-4 Receptor Human genes 0.000 claims description 15
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 claims description 15
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 claims description 15
- 108010081735 N-Ethylmaleimide-Sensitive Proteins Proteins 0.000 claims description 15
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 15
- 102100035054 Vesicle-fusing ATPase Human genes 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 108091006112 ATPases Proteins 0.000 claims description 13
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 13
- 102000007456 Peroxiredoxin Human genes 0.000 claims description 13
- 108010012822 Peroxiredoxin III Proteins 0.000 claims description 13
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 13
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 13
- 102100038517 Pyridoxal kinase Human genes 0.000 claims description 13
- 102100022308 Ras-related protein Rab-3A Human genes 0.000 claims description 13
- 102100034769 Thioredoxin-dependent peroxide reductase, mitochondrial Human genes 0.000 claims description 13
- 230000002132 lysosomal effect Effects 0.000 claims description 13
- 108030002458 peroxiredoxin Proteins 0.000 claims description 13
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 12
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 12
- 102000006027 3-hydroxyisobutyrate dehydrogenase Human genes 0.000 claims description 12
- 108020003281 3-hydroxyisobutyrate dehydrogenase Proteins 0.000 claims description 12
- 102100038910 Alpha-enolase Human genes 0.000 claims description 12
- 101710165425 Alpha-enolase Proteins 0.000 claims description 12
- 108090000656 Annexin A6 Proteins 0.000 claims description 12
- 102000004154 Annexin A6 Human genes 0.000 claims description 12
- 108010077173 BB Form Creatine Kinase Proteins 0.000 claims description 12
- 108010028326 Calbindin 2 Proteins 0.000 claims description 12
- 102000004631 Calcineurin Human genes 0.000 claims description 12
- 108010042955 Calcineurin Proteins 0.000 claims description 12
- 102100021849 Calretinin Human genes 0.000 claims description 12
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims description 12
- 102100023508 Chloride intracellular channel protein 4 Human genes 0.000 claims description 12
- 102100022785 Creatine kinase B-type Human genes 0.000 claims description 12
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 claims description 12
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 claims description 12
- 102100024443 Dihydropyrimidinase-related protein 4 Human genes 0.000 claims description 12
- 101710184673 Enolase 1 Proteins 0.000 claims description 12
- 102100022277 Fructose-bisphosphate aldolase A Human genes 0.000 claims description 12
- 102100027269 Fructose-bisphosphate aldolase C Human genes 0.000 claims description 12
- 102000034286 G proteins Human genes 0.000 claims description 12
- 108091006027 G proteins Proteins 0.000 claims description 12
- 102100028652 Gamma-enolase Human genes 0.000 claims description 12
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 claims description 12
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 12
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 claims description 12
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 claims description 12
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 12
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 12
- 101000906636 Homo sapiens Chloride intracellular channel protein 4 Proteins 0.000 claims description 12
- 101001053490 Homo sapiens Dihydropyrimidinase-related protein 4 Proteins 0.000 claims description 12
- 101000755879 Homo sapiens Fructose-bisphosphate aldolase A Proteins 0.000 claims description 12
- 101000836545 Homo sapiens Fructose-bisphosphate aldolase C Proteins 0.000 claims description 12
- 101001098802 Homo sapiens Protein disulfide-isomerase A3 Proteins 0.000 claims description 12
- 101000620561 Homo sapiens Ras-related protein Rab-3A Proteins 0.000 claims description 12
- 101001077400 Homo sapiens Ras-related protein Rab-6A Proteins 0.000 claims description 12
- 101000625727 Homo sapiens Tubulin beta chain Proteins 0.000 claims description 12
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 claims description 12
- 101000934581 Homo sapiens Valacyclovir hydrolase Proteins 0.000 claims description 12
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 claims description 12
- 101710185553 Malate dehydrogenase, cytoplasmic Proteins 0.000 claims description 12
- 102100026475 Malate dehydrogenase, cytoplasmic Human genes 0.000 claims description 12
- 102000010751 Neurocalcin Human genes 0.000 claims description 12
- 108010077960 Neurocalcin Proteins 0.000 claims description 12
- 102100023057 Neurofilament light polypeptide Human genes 0.000 claims description 12
- 101710143604 Neurofilament light polypeptide Proteins 0.000 claims description 12
- 102100028489 Phosphatidylethanolamine-binding protein 1 Human genes 0.000 claims description 12
- 108010064785 Phospholipases Proteins 0.000 claims description 12
- 102000015439 Phospholipases Human genes 0.000 claims description 12
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims description 12
- 102000011195 Profilin Human genes 0.000 claims description 12
- 108050001408 Profilin Proteins 0.000 claims description 12
- 108050003974 Profilin-2 Proteins 0.000 claims description 12
- 101710186654 Proteasome subunit alpha type-2 Proteins 0.000 claims description 12
- 102100040364 Proteasome subunit alpha type-2 Human genes 0.000 claims description 12
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 claims description 12
- 102000015176 Proton-Translocating ATPases Human genes 0.000 claims description 12
- 108010039518 Proton-Translocating ATPases Proteins 0.000 claims description 12
- 102100025219 Ras-related protein Rab-6A Human genes 0.000 claims description 12
- 108700004754 S pombe hsp9 Proteins 0.000 claims description 12
- 102100022760 Stress-70 protein, mitochondrial Human genes 0.000 claims description 12
- 102000016593 Transgelin-3 Human genes 0.000 claims description 12
- 108050006165 Transgelin-3 Proteins 0.000 claims description 12
- 102100033598 Triosephosphate isomerase Human genes 0.000 claims description 12
- 101710194411 Triosephosphate isomerase 1 Proteins 0.000 claims description 12
- 102000004243 Tubulin Human genes 0.000 claims description 12
- 108090000704 Tubulin Proteins 0.000 claims description 12
- 102100024717 Tubulin beta chain Human genes 0.000 claims description 12
- 102100036790 Tubulin beta-3 chain Human genes 0.000 claims description 12
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 claims description 12
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 claims description 12
- 102100025139 Valacyclovir hydrolase Human genes 0.000 claims description 12
- 229960000846 camphor Drugs 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 12
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 12
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 claims description 12
- 230000000926 neurological effect Effects 0.000 claims description 12
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 102100027757 ATP synthase subunit d, mitochondrial Human genes 0.000 claims description 11
- 102100024075 Alpha-internexin Human genes 0.000 claims description 11
- 102100028252 Brain acid soluble protein 1 Human genes 0.000 claims description 11
- 101710171534 Cytochrome b-c1 complex subunit 1, mitochondrial Proteins 0.000 claims description 11
- 102100039924 Cytochrome b-c1 complex subunit 1, mitochondrial Human genes 0.000 claims description 11
- 102100027152 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Human genes 0.000 claims description 11
- 102300048361 Glyceraldehyde-3-phosphate dehydrogenase isoform 1 Human genes 0.000 claims description 11
- 102100039392 Haloacid dehalogenase-like hydrolase domain-containing protein 2 Human genes 0.000 claims description 11
- 101000936976 Homo sapiens ATP synthase subunit d, mitochondrial Proteins 0.000 claims description 11
- 101000833549 Homo sapiens Alpha-internexin Proteins 0.000 claims description 11
- 101000935689 Homo sapiens Brain acid soluble protein 1 Proteins 0.000 claims description 11
- 101001122360 Homo sapiens Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Proteins 0.000 claims description 11
- 101001035680 Homo sapiens Haloacid dehalogenase-like hydrolase domain-containing protein 2 Proteins 0.000 claims description 11
- 101001042036 Homo sapiens Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial Proteins 0.000 claims description 11
- 101001099586 Homo sapiens Pyridoxal kinase Proteins 0.000 claims description 11
- 101000584908 Homo sapiens Ras-related protein Rab-1B Proteins 0.000 claims description 11
- 102100021332 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial Human genes 0.000 claims description 11
- 102100034335 Rab GDP dissociation inhibitor alpha Human genes 0.000 claims description 11
- 101710102264 Rab GDP dissociation inhibitor alpha Proteins 0.000 claims description 11
- 102100029979 Ras-related protein Rab-1B Human genes 0.000 claims description 11
- 230000004069 differentiation Effects 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 208000028683 bipolar I disease Diseases 0.000 claims description 10
- 206010015037 epilepsy Diseases 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 10
- 230000009529 traumatic brain injury Effects 0.000 claims description 10
- 208000025307 bipolar depression Diseases 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims description 8
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 8
- 150000003943 catecholamines Chemical class 0.000 claims description 8
- 230000019771 cognition Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 230000006931 brain damage Effects 0.000 claims description 6
- 231100000874 brain damage Toxicity 0.000 claims description 6
- 208000029028 brain injury Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 4
- 108091006146 Channels Proteins 0.000 claims description 4
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 4
- 229940124604 anti-psychotic medication Drugs 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 102400000058 Neuregulin-1 Human genes 0.000 abstract description 79
- 108090000556 Neuregulin-1 Proteins 0.000 abstract description 77
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 235000018102 proteins Nutrition 0.000 description 138
- 235000001014 amino acid Nutrition 0.000 description 97
- 229940024606 amino acid Drugs 0.000 description 92
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 87
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 49
- 241000282414 Homo sapiens Species 0.000 description 43
- 210000005064 dopaminergic neuron Anatomy 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 38
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 35
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 35
- 238000002347 injection Methods 0.000 description 31
- 239000007924 injection Substances 0.000 description 31
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 29
- 238000007912 intraperitoneal administration Methods 0.000 description 28
- 102000039446 nucleic acids Human genes 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 27
- 239000011780 sodium chloride Substances 0.000 description 26
- 230000001965 increasing effect Effects 0.000 description 25
- 210000004556 brain Anatomy 0.000 description 24
- 210000001259 mesencephalon Anatomy 0.000 description 22
- 230000003291 dopaminomimetic effect Effects 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 230000008499 blood brain barrier function Effects 0.000 description 18
- 210000001218 blood-brain barrier Anatomy 0.000 description 18
- 230000004031 neuronal differentiation Effects 0.000 description 18
- 210000001577 neostriatum Anatomy 0.000 description 17
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 210000004498 neuroglial cell Anatomy 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 108010026552 Proteome Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 208000004296 neuralgia Diseases 0.000 description 10
- 230000004112 neuroprotection Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 8
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- -1 aromatic amino acid Chemical class 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 230000024245 cell differentiation Effects 0.000 description 8
- 230000007850 degeneration Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 210000005153 frontal cortex Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002297 mitogenic effect Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 208000021642 Muscular disease Diseases 0.000 description 6
- 201000009623 Myopathy Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000010150 least significant difference test Methods 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 230000010627 oxidative phosphorylation Effects 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 230000003376 axonal effect Effects 0.000 description 5
- 229960004170 clozapine Drugs 0.000 description 5
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003492 excitotoxic effect Effects 0.000 description 5
- 231100000063 excitotoxicity Toxicity 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 210000003963 intermediate filament Anatomy 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 230000004766 neurogenesis Effects 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 201000001119 neuropathy Diseases 0.000 description 5
- 230000007823 neuropathy Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 229960005017 olanzapine Drugs 0.000 description 5
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 208000033808 peripheral neuropathy Diseases 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 210000003523 substantia nigra Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
- 241001573498 Compacta Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000002488 pyknotic effect Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 210000004116 schwann cell Anatomy 0.000 description 4
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 3
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000001029 dorsal striatum Anatomy 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 210000001030 ventral striatum Anatomy 0.000 description 3
- 230000028973 vesicle-mediated transport Effects 0.000 description 3
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 2
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 2
- 102100024426 Dihydropyrimidinase-related protein 2 Human genes 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 2
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 108090000143 Mouse Proteins Proteins 0.000 description 2
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 101800002648 Neuregulin-1 Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010070648 Pyridoxal Kinase Proteins 0.000 description 2
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 102000003802 alpha-Synuclein Human genes 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 108010022822 collapsin response mediator protein-2 Proteins 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 150000002016 disaccharides Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000055650 human NRG1 Human genes 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102200036626 rs104893877 Human genes 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 210000004515 ventral tegmental area Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 102400000574 Amyloid-beta protein 42 Human genes 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108010028196 Dihydropteridine Reductase Proteins 0.000 description 1
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 208000033618 Elevated mood Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150004694 Erbb4 gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102000014348 Haloacid dehalogenase-like hydrolases Human genes 0.000 description 1
- 108050003363 Haloacid dehalogenase-like hydrolases Proteins 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100025184 Mitogen-activated protein kinase kinase kinase 13 Human genes 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000004390 N-Ethylmaleimide-Sensitive Proteins Human genes 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 101800000675 Neuregulin-2 Proteins 0.000 description 1
- 102400000055 Neuregulin-4 Human genes 0.000 description 1
- 101800002641 Neuregulin-4 Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000221946 Podospora anserina Species 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710150593 Protein beta Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020005161 RNA Caps Proteins 0.000 description 1
- 102000028391 RNA cap binding Human genes 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000037169 Retrograde Degeneration Diseases 0.000 description 1
- 101001124028 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Non-structural maintenance of chromosome element 6 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
- 241000615754 Tentorium Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102000036208 glycosaminoglycan binding proteins Human genes 0.000 description 1
- 108091010992 glycosaminoglycan binding proteins Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003379 hyperdopaminergic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000005049 internexin Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004189 ion pair high performance liquid chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000001010 olfactory tubercle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 102000034272 protein filaments Human genes 0.000 description 1
- 108091005974 protein filaments Proteins 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010046566 rab3A GTP Binding Protein Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000014848 ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127033831A KR20130113962A (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
US13/700,209 US20130072437A1 (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms,neuregulin polypeptides and uses thereof |
EP11721562.4A EP2575862A2 (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
CN2011800314094A CN103118698A (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
BR112012030331A BR112012030331A2 (en) | 2010-05-28 | 2011-05-27 | neuregulin isoforms, neuregulin polypeptides, and uses thereof |
JP2013512852A JP2013529911A (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoform, neuregulin polypeptide and methods of use thereof |
MX2012013735A MX2012013735A (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms, neuregulin polypeptides and uses thereof. |
AU2011257192A AU2011257192A1 (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
CA2800766A CA2800766A1 (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
RU2012157572/10A RU2012157572A (en) | 2010-05-28 | 2011-05-27 | NEYREGULIN ISOFORM, NEUREGULIN POLYPEPTIDES AND THEIR APPLICATION |
IL222966A IL222966A0 (en) | 2010-05-28 | 2012-11-11 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
US14/550,338 US20150080302A1 (en) | 2010-05-28 | 2014-11-21 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34945110P | 2010-05-28 | 2010-05-28 | |
US61/349,451 | 2010-05-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/700,209 A-371-Of-International US20130072437A1 (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms,neuregulin polypeptides and uses thereof |
US14/550,338 Continuation US20150080302A1 (en) | 2010-05-28 | 2014-11-21 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011147981A2 true WO2011147981A2 (en) | 2011-12-01 |
WO2011147981A3 WO2011147981A3 (en) | 2012-02-02 |
Family
ID=44343932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/058769 WO2011147981A2 (en) | 2010-05-28 | 2011-05-27 | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130072437A1 (en) |
EP (1) | EP2575862A2 (en) |
JP (1) | JP2013529911A (en) |
KR (1) | KR20130113962A (en) |
CN (1) | CN103118698A (en) |
AU (1) | AU2011257192A1 (en) |
BR (1) | BR112012030331A2 (en) |
CA (1) | CA2800766A1 (en) |
IL (1) | IL222966A0 (en) |
MX (1) | MX2012013735A (en) |
RU (1) | RU2012157572A (en) |
WO (1) | WO2011147981A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014051567A1 (en) * | 2012-09-26 | 2014-04-03 | Morehouse School Of Medicine | Chimeric neuregulins and method of making and use thereof |
WO2017108419A1 (en) * | 2015-12-22 | 2017-06-29 | Nestec S.A. | Methods for treating sarcopenia and frailty |
US10188707B2 (en) | 2014-01-13 | 2019-01-29 | Berg, LLC | Enolase 1 (Eno1) compositions and uses thereof |
US10557859B2 (en) | 2015-05-05 | 2020-02-11 | The Regents Of The University Of California | Astrocyte traumatome and neurotrauma biomarkers |
CN112481246A (en) * | 2020-12-16 | 2021-03-12 | 熊猫乳品集团股份有限公司 | Bioactive polypeptide FSPANKKLTPKKY, and preparation method and application thereof |
US11426447B2 (en) * | 2016-04-19 | 2022-08-30 | Leibniz-Institut Fur Alternsforschung—Fritz-Lipmann-Institut E.V. (Fli) | Neuregulin for the treatment of tumors of the nervous system |
US11709168B2 (en) | 2017-05-23 | 2023-07-25 | Brainbox Solutions, Inc. | Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10199266B2 (en) | 2016-12-26 | 2019-02-05 | Intel Corporation | Integrated circuit interconnect structure having metal oxide adhesive layer |
CA3064352A1 (en) * | 2017-05-24 | 2018-11-29 | Thoeris Gmbh | Use of glutamine synthetase for treating hyperammonemia |
CN108421032A (en) * | 2018-05-14 | 2018-08-21 | 南方医科大学 | Neuregulin 1 is preparing the application in treating adolescent depression disease drug |
JP2021524467A (en) * | 2018-05-23 | 2021-09-13 | メニスマート セラピューティクス, インコーポレイテッドManysmart Therapeutics, Inc. | Bispecific T cell derivatives and their use |
CN110946991A (en) * | 2018-09-27 | 2020-04-03 | 广州中医药大学(广州中医药研究院) | Application of neuregulin1 |
CN112438990A (en) * | 2019-08-29 | 2021-03-05 | 鲁南制药集团股份有限公司 | New use of heparin, or derivative or pharmaceutically acceptable salt thereof |
CN110721307A (en) * | 2019-12-03 | 2020-01-24 | 广州中医药大学(广州中医药研究院) | Application of neuregulin 1 in preparing product for enhancing TRPC6 channel activity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006008118A1 (en) | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7285531B1 (en) * | 1991-04-10 | 2007-10-23 | Acorda Therapeutics, Inc. | Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor |
US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
AU7042994A (en) * | 1993-05-21 | 1994-12-20 | Amgen, Inc. | Recombinant (neu) differentiation factors |
ATE427353T1 (en) * | 1997-02-10 | 2009-04-15 | Genentech Inc | HEREGULIN VARIANTS |
US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
US7527794B2 (en) * | 2001-07-31 | 2009-05-05 | Wayne State University | Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
US7191068B2 (en) * | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
EP1824879B1 (en) * | 2004-07-09 | 2014-10-29 | Wayne State University | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING |
EP1890722A2 (en) * | 2005-05-27 | 2008-02-27 | Five Prime Therapeutics, Inc. | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
AU2009217606B2 (en) * | 2008-02-29 | 2015-03-05 | Acorda Therapeutics, Inc. | Method for achieving desired glial growth factor 2 plasma levels |
WO2009137837A2 (en) * | 2008-05-09 | 2009-11-12 | The Regents Of The University Of California | Neuregulin/erbb signaling and integrin |
US9498515B2 (en) * | 2008-08-15 | 2016-11-22 | Acorda Therapeutics, Inc. | Compositions and methods for treatment during non-acute periods following CNS neurological injury |
-
2011
- 2011-05-27 RU RU2012157572/10A patent/RU2012157572A/en not_active Application Discontinuation
- 2011-05-27 WO PCT/EP2011/058769 patent/WO2011147981A2/en active Application Filing
- 2011-05-27 MX MX2012013735A patent/MX2012013735A/en not_active Application Discontinuation
- 2011-05-27 JP JP2013512852A patent/JP2013529911A/en active Pending
- 2011-05-27 EP EP11721562.4A patent/EP2575862A2/en not_active Withdrawn
- 2011-05-27 KR KR1020127033831A patent/KR20130113962A/en not_active Application Discontinuation
- 2011-05-27 US US13/700,209 patent/US20130072437A1/en not_active Abandoned
- 2011-05-27 BR BR112012030331A patent/BR112012030331A2/en not_active IP Right Cessation
- 2011-05-27 CA CA2800766A patent/CA2800766A1/en not_active Abandoned
- 2011-05-27 CN CN2011800314094A patent/CN103118698A/en active Pending
- 2011-05-27 AU AU2011257192A patent/AU2011257192A1/en not_active Abandoned
-
2012
- 2012-11-11 IL IL222966A patent/IL222966A0/en unknown
-
2014
- 2014-11-21 US US14/550,338 patent/US20150080302A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006008118A1 (en) | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
WO2006008119A1 (en) | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
Non-Patent Citations (38)
Title |
---|
"A multilingual glossary of biotechnological terms: (IUPAC Recommendations", 1995, HELVETICA CHIMICA ACTA |
"Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", 1996, CRC PRESS |
"United States Pharmacopeia-25/National Formulary-20", 2001, UNITED STATES PHARMCOPEIAL CONVENTION, INC. |
ALTSCHUL, S. F., GISH, W., MILLER, W., MYERS, E. W., LIPMAN, D. J.: "Basic local alignment search tool", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410, XP002949123, DOI: doi:10.1006/jmbi.1990.9999 |
ALTSCHUL, S. F., MADDEN T. L., SCHAFFER, A. A., ZHANG, J., ZHANG, Z., MILLER, W., LIPMAN, D. J.: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402, XP002905950, DOI: doi:10.1093/nar/25.17.3389 |
ALVAREZ-FISCHER, D. ET AL.: "Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice", EXP. NEUROL., vol. 210, 2008, pages 182 - 193, XP026784184, DOI: doi:10.1016/j.expneurol.2007.10.012 |
AXEL KLEEMANN, JURGEN ENGEL: "Pharmaceutical Substances: Syntheses, Patents, Applications", 1999, THIEME MEDICAL PUBLISHING |
BEHRSTOCK,S., BEHRSTOCK,S., EBERT,A., MCHUGH,J., VOSBERG,S., MOORE,J., SCHNEIDER,B., CAPOWSKI,E., HEI,D., KORDOWER,J.: "Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates", GENE THER., vol. 13, 2006, pages 379 - 388, XP055007837, DOI: doi:10.1038/sj.gt.3302679 |
CANNELLA B, PITT D, MARCHIONNI M, RAINE CS: "Neuregulin and erbB receptor expression in normal and diseased human white matter", J NEUROIMMUNOL, vol. 100, 1999, pages 233 - 242, XP002375867, DOI: doi:10.1016/S0165-5728(99)00201-5 |
CHAUDHURY AR, GERECKE KM, WYSS JM, MORGAN DG, GORDON MN, CARROLL SL: "Neuregulin-I and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease", J NEUROPATHOL EXP NEUROL, vol. 62, 2003, pages 42 - 54 |
CHESSELET MF: "In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?", EXP NEUROL., vol. 209, no. 1, January 2008 (2008-01-01), pages 22 - 7, XP022588918, DOI: doi:10.1016/j.expneurol.2007.08.006 |
DAUER,W., PRZEDBORSKI,S.: "Parkinson's disease: mechanisms and models", NEURON, vol. 39, 2003, pages 889 - 909, XP002593276 |
GILL,S.S., PATEL,N.K., HOTTON,G.R., O'SULLIVAN,K., MCCARTER,R., BUNNAGE,M., BROOKS,D.J., SVENDSEN,C.N., HEYWOOD,P.: "Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease", NAT. MED., vol. 9, 2003, pages 589 - 595, XP002427989, DOI: doi:10.1038/nm850 |
GISH, W., STATES, D. J.: "Identification of protein coding regions by database similarity search", NATURE GENET., vol. 3, 1993, pages 266 - 272 |
GITLER,A.D., BEVIS,B.J., SHORTER,J., STRATHEARN,K.E., HAMAMICHI,S., SU,L.J., CALDWELL,K.A., CALDWELL,G.A., ROCHET,J.C., MCCAFFERY,, THE PARKINSON'S DISEASE PROTEIN ALPHA-SYNUCLEIN DISRUPTS CELLULAR RAB HOMEOSTASIS PNAS, vol. 105, 2008, pages 145 - 150 |
GROEBE,K. ET AL.: "Differential proteomic profiling of mitochondria from Podospora anserina, rat and human reveals distinct patterns of age-related oxidative changes", EXP. GERONTOL., vol. 42, 2007, pages 887 - 898 |
HARVEY BK, WANG Y, HOFFER BJ: "Transgenic rodent models of Parkinson's disease", ACTA NEUROCHIR SUPPL., vol. 101, 2008, pages 89 - 92 |
HILEMAN: "BioEssays", vol. 20, 1998, JOHN WILEY & SONS, INC., article "Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins", pages: 156 - 167 |
KASTIN,A.J., AKERSTROM,V., PAN,W.: "Neuregulin-1-betal enters brain and spinal cord by receptor-mediated transport", J NEUROCHEM., vol. 88, 2004, pages 965 - 970, XP009175039 |
KORDOWER,J.H., EMBORG,M.E., BLOCH,J., MA,S.Y., CHU,Y., LEVENTHAL,L., MCBRIDE,J., CHEN,E.Y., PALFI,S., ROITBERG,B.Z.: "Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease", SCIENCE, vol. 290, 2000, pages 767 - 773, XP002207711, DOI: doi:10.1126/science.290.5492.767 |
LANG,A.E. GILL,S., PATEL,N.K., LOZANO,A., NUTT,J.G., PENN,R., BROOKS,D.J., HOTTON,G., MORO,E., HEYWOOD,P., BRODSKY,M.A.: "Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease", ANN. NEUROL., vol. 59, 2006, pages 459 - 466 |
LIN, L.F., DOHERTY,D.H., LILE,J.D., BEKTESH,S., COLLINS,F.: "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons", SCIENCE, vol. 260, 1993, pages 1130 - 1132, XP002914283, DOI: doi:10.1126/science.8493557 |
LOEB, J. A., FISCHBACH, G. D., J. CELL BIOL., vol. 130, 1995, pages 127 - 135 |
LOTHARIUS,J., FALSIG,J., VAN,BEEK J., PAYNE,S., DRINGEN,R., BRUNDIN,P., LEIST,M.: "Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway", J. NEUROSCI., vol. 25, 2005, pages 6329 - 6342 |
MADDEN, T. L., TATUSOV, R. L., ZHANG, J.: "Applications of network BLAST server", METH. ENZYMOL., vol. 266, 1996, pages 131 - 141, XP001006313, DOI: doi:10.1016/S0076-6879(96)66011-X |
MEYER-LUEHMANN,M., COOMARASWAMY,J., BOLMONT,T., KAESER,S., SCHAEFER,C., KILGER,E., NEUENSCHWANDER,A., ABRAMOWSKI,D., FREY,P., JATO: "Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host", SCIENCE, vol. 313, 2006, pages 1781 - 1784, XP055120290, DOI: doi:10.1126/science.1131864 |
MIZUNO Y, OHTA S, TANAKA M, TAKAMIYA S, SUZUKI K, SATO T, OYA H, OZAWA T, KAGAWA Y: "Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease", BIOCHEM BIOPHYS RES COMMUN., vol. 163, no. 3, 29 September 1989 (1989-09-29), pages 1450 - 5, XP024836776, DOI: doi:10.1016/0006-291X(89)91141-8 |
NISSOU, M., BENABID, A.L., SADOUL, R., VERNA, J.M.: "Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease", PROG. NEUROBIOL., vol. 65, 2001, pages 135 - 172 |
POZNANOVIC,S., SCHWALL,G., ZENGERLING,H., CAHILL,M.A.: "Isoelectric focusing in serial immobilized pH gradient gels to improve protein separation in proteomic analysis", ELECTROPHORESIS, vol. 26, 2005, pages 3185 - 3190, XP055083662, DOI: doi:10.1002/elps.200500224 |
RADDE,R., BOLMONT,T., KAESER,S.A., COOMARASWAMY,J., LINDAU,D., STOLTZE,L., CALHOUN,M.E., JAGGI,F., WOLBURG,H., GENGLER,S.: "Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology", EMBO REPORT, vol. 7, 2006, pages 940 - 946 |
SCHILDKNECHT,S., POLTL,D., NAGEL,D.M., MATT,F., SCHOLZ,D., LOTHARIUS,J., SCHMIEG,N., SALVO-VARGAS,A., LEIST,M.: "Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells, Toxicol", APPLIED PHARMACOL, vol. 241, 2009, pages 23 - 35, XP026699742, DOI: doi:10.1016/j.taap.2009.07.027 |
SCHRATTENHOLZ ET AL., CURRENT TOPICS IN MEDICAL CHEMISTRY, vol. 6, 2006, pages 663 - 586 |
STEINER,H., BLUM,M., KITAI,S.T., FEDI,P.: "Differential expression of ErbB3 and ErbB4 neuregulin receptors in dopamine neurons and forebrain areas of the adult rat", EXP. NEUROL., vol. 159, 1999, pages 494 - 503 |
THOENEN,H., SENDTNER,M.: "Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches", NAT. NEUROSCI., vol. 5, 2002, pages 1046 - 1050, XP002533045, DOI: doi:10.1038/NN938 |
TOKITA Y, KEINO H, MATSUI F, AONO S, ISHIGURO H, HIGASHIYAMA S, OOHIRA A: "Regulation of Neuregulin Expression in the Injured Rat Brain and Cultured Astrocytes", J NEUROSCI, vol. 21, 2001, pages 1257 - 1264, XP009162207, DOI: doi:10.1016/S0168-0102(00)81603-X |
VOORN,P., VANDERSCHUREN,L.J., GROENEWEGEN,H.J., ROBBINS,T.W., PENNARTZ,C.M.: "Putting a spin on the dorsal-ventral divide of the striatum", TRENDS NEUROSCI., vol. 27, 2004, pages 468 - 474, XP004522852, DOI: doi:10.1016/j.tins.2004.06.006 |
WOOD-KACZMAR,A., GANDHI,S., WOOD,N.W.: "Understanding the molecular causes of Parkinson's disease", TRENDS MOL. MED, vol. 12, 2006, pages 521 - 528, XP028058727, DOI: doi:10.1016/j.molmed.2006.09.007 |
ZHANG,L., FLETCHER-TURNER,A., MARCHIONNI,M.A., APPARSUNDARAM,S., LUNDGREN,K.H., YUREK,D.M., SEROOGY,K.B.: "Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures", J NEUROCHEM., vol. 91, 2004, pages 1358 - 1368, XP002518764, DOI: doi:10.1111/J.1471-4159.2004.02817.X |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014051567A1 (en) * | 2012-09-26 | 2014-04-03 | Morehouse School Of Medicine | Chimeric neuregulins and method of making and use thereof |
US10188707B2 (en) | 2014-01-13 | 2019-01-29 | Berg, LLC | Enolase 1 (Eno1) compositions and uses thereof |
US10188708B2 (en) | 2014-01-13 | 2019-01-29 | Berg Llc | Enolase 1 (Eno1) compositions and uses thereof |
US11224641B2 (en) | 2014-01-13 | 2022-01-18 | Berg Llc | Enolase 1 (ENO1) compositions and uses thereof |
US10557859B2 (en) | 2015-05-05 | 2020-02-11 | The Regents Of The University Of California | Astrocyte traumatome and neurotrauma biomarkers |
US11249094B2 (en) | 2015-05-05 | 2022-02-15 | The Regents Of The University Of California | Astrocyte traumatome and neurotrauma biomarkers |
WO2017108419A1 (en) * | 2015-12-22 | 2017-06-29 | Nestec S.A. | Methods for treating sarcopenia and frailty |
US10758560B2 (en) | 2015-12-22 | 2020-09-01 | Societe Des Produits Nestle S.A. | Methods for treating sarcopenia and frailty |
US11426447B2 (en) * | 2016-04-19 | 2022-08-30 | Leibniz-Institut Fur Alternsforschung—Fritz-Lipmann-Institut E.V. (Fli) | Neuregulin for the treatment of tumors of the nervous system |
US11709168B2 (en) | 2017-05-23 | 2023-07-25 | Brainbox Solutions, Inc. | Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma |
CN112481246A (en) * | 2020-12-16 | 2021-03-12 | 熊猫乳品集团股份有限公司 | Bioactive polypeptide FSPANKKLTPKKY, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2800766A1 (en) | 2011-12-01 |
BR112012030331A2 (en) | 2017-06-20 |
US20150080302A1 (en) | 2015-03-19 |
RU2012157572A (en) | 2014-07-10 |
MX2012013735A (en) | 2013-04-29 |
KR20130113962A (en) | 2013-10-16 |
JP2013529911A (en) | 2013-07-25 |
WO2011147981A3 (en) | 2012-02-02 |
CN103118698A (en) | 2013-05-22 |
US20130072437A1 (en) | 2013-03-21 |
IL222966A0 (en) | 2013-02-03 |
EP2575862A2 (en) | 2013-04-10 |
AU2011257192A1 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150080302A1 (en) | Neuregulin isoforms, neuregulin polypeptides and uses thereof | |
ES2380055T3 (en) | Modulation of neurotrophin activity; scrutiny method | |
Thakker-Varia et al. | Neuropeptides in depression: role of VGF | |
Zhou et al. | Distribution and localization of pro‐brain‐derived neurotrophic factor‐like immunoreactivity in the peripheral and central nervous system of the adult rat | |
US6696303B2 (en) | Identifying substances using cells that express p75NTR | |
EP3225251B1 (en) | Modulation of activity of proneurotrophins | |
WO1998022499A2 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
WO1998022499A9 (en) | Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof | |
CN110256574B (en) | Fusion polypeptide and application thereof in preparing medicament for resisting depression and neurodegenerative diseases | |
EP3870290A1 (en) | Inhibitors of pick1 and uses thereof | |
WO1993009798A1 (en) | Therapeutic and diagnostic methods based on tissue specific nt-3 expression and receptor binding | |
Salek et al. | Spinophilin‐dependent regulation of GluN2B‐containing NMDAR‐dependent calcium influx, GluN2B surface expression, and cleaved caspase expression | |
US20150344535A1 (en) | Neurotrophin-tyrosine kinase receptor signaling | |
JP5939528B2 (en) | Pharmaceutical composition comprising calmodulin-like skin protein as an active ingredient | |
WO2004050114A1 (en) | Novel agent for improving neurotransmission failure | |
US20220275038A1 (en) | Clsp derivative incapable of being affected by clsp inhibiting substance, and clsp activity enhancing/protecting agent | |
US20050233955A1 (en) | Stimulation of nerve cell regeneration | |
CA2221391A1 (en) | Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof | |
Sairanen | Neurotrophins and neuronal plasticity in the action of antidepressants and morphine | |
Jin | The characterization of a secreted form of amyloid beta/A4 protein precursor as a neurotrophic factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180031409.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11721562 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 222966 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10116/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2800766 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13700209 Country of ref document: US Ref document number: MX/A/2012/013735 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2013512852 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011721562 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20127033831 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2012157572 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011257192 Country of ref document: AU Date of ref document: 20110527 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012030331 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012030331 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121128 |